No Added Benefit Of Ingenol Mebutate For Actinic Keratosis

Manufacturer's dossier did not contain any relevant data for the comparison with diclofenac/hyaluronic acid gel The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Dermatology Source Type: news